Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer’s therapy, Leqembi (lecanemab), is now available in China, the companies announced late Thursday. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and said to be the only approved treatment shown to reduce the rate of disease progressionContinue Reading
MicroStockHub X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4 (XFOR) markets asContinue Reading
skynesher/E+ via Getty Images Lantheus Holdings (NASDAQ:LNTH) Thursday announced its acquisition of the global rights of Life Molecular Imaging’s RM2, targeting the gastrin-releasing peptide receptor, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair. This acquisition strengthens Lantheus’ (LNTH) presence in prostate cancer and expands its pipeline to include breastContinue Reading
Grandbrothers/iStock Editorial via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS) traded higher Tuesday after the U.S. FDA accepted to review a marketing application for its anti-lipid therapy olezarsen, targeted at a rare genetic condition known as familial chylomicronemia syndrome (FCA). Granting priority review for Ionis’ (IONS) New Drug Application (NDA) for olezarsen,Continue Reading
jetcityimage/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been surgically removed. Citing data from a Phase 3 trial called ADJUVANT BR.31, the company said Imfinzi did not demonstrateContinue Reading
RomanBabakin Sanofi (NASDAQ:SNY) is up ~3% in Monday afternoon trading as it stands to benefit from positive data released earlier in the day on Alnylam Pharmaceuticals’ (ALNY) Amvuttra (vutrisiran) The data was on the drug in treating ATTR amyloidosis with cardiomyopathy. The therapoy was already approved for polyneuropathy of hereditaryContinue Reading
phototechno Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday. TheContinue Reading
